UK small-cap RNS · 26 Jun 2026
Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.
Sort: Newest · Largest companies
-
15:25
Caspian Sunrise CASP £45mDelay to Publication of 31 Dec 2025 Results ResultsCaspian Sunrise PLC ("Caspian Sunrise" or the "Group")−7.1% on the day
-
11:00
Annual Report and Notice of AGM ResultsInspiration Healthcare Group plc (AIM: IHC), the global medical technology company, pioneering, specialist neonatal intensive care medical devices, announces that the Annual Report and Accounts for the year ended 31 January 2026 and the Notice of Annual …−4.4% on the day
-
07:21
Audited 2025 Annual Report and Notice of AGM ResultsAudited FY25 accounts match the 15 June figures: EBITDA down 54% to USD 42.7m after the Search reset, with a USD 41.7m Search impairment. Nothing new, and 2026 expectations are only reiterated.in lineoutlook positive +0.9% on the day
-
07:00
Results of Fundraising ResultsThe placing completed at 1p, a 24.81% discount to the prior close, issuing 400m shares and lifting the share count to about 2.87bn. It funds a pre-revenue company but dilutes holders heavily.Moved: Discounted placing of up to £4m: Accelerated bookbuild launched; broker offer open → Placing completed, oversubscribed; admission pending
-
07:00
Investor Presentation covering Full Year Results ResultsPolar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, is pleased to announce that Iain Evans, CEO, and Samir Ayub, CFO, will be conducting a live online presentation covering the Group's results for the …−0.6% on the day
-
07:00
Final Results ResultsArc Minerals (LSE: ARCM), an exploration company focused on discovering and developing Tier 1 copper deposits in Africa, is pleased to announce its Final Results for the year ended 31 December 2025.first in 9 months −19.0% on the day
-
07:00
Kistos Holdings KIST £254m2025 Full Year Results ResultsFull-year results for the year ended 31 December 2025first in 9 months +0.0% on the day
-
07:00
Final Results ResultsLoss widened to £1.90m from £0.61m as R&D rose to £908k ahead of the Phase 2 trial; cash was £1.13m at year end, but regulatory milestones were met and funding has since been added.Moved: Irinotecan-ChemoSeed glioblastoma Phase 2: First batch made; dosing guided to H1 2026 → Funded; manufacturing done, site activation advanced
-
07:00
-
07:00
Thruvision Group THRU £8.5mResults for the year ended 31 March 2026 ResultsFY26 results match the revenue given on 8 April and EBITDA in line with market expectations. The Board adds no numeric guidance, only confidence in FY27 growth, so this is not a raise.Balance-sheet stress / refinancing £6.0m · 71% of mcapin lineoutlook positivefirst since Oct 2023 +0.0% on the dayMoved: Going concern and cash runway: FY26 revenue in range; cash £2.0m → FY26 results: cash £2.0m, no debt · Pricing and cost reset: Box Clever in progress; subscription launched → Initial savings achieved early FY27